Stock listing

Frankfurt:V5Z Sirnaomics Ltd. Aktie

German listing (Frankfurt) of Sirnaomics Ltd. · home listing HKEX:2257

Follow Sirnaomics Ltd. into a list and get an email when it puts out news.

Share price · FWB:V5Z

€0.398 EUR -0.038 (-8.7%)

Close on Nov 20, 2026

This year -48.1% · daily closes, Dec 1, 2025 – Nov 6, 2026, adjusted for splits
Day range
€0.398 – €0.404 EURNov 20, 2026
Market cap
€44.31M EURAt the close on Nov 20, 2026 · price × 111.3M shares outstanding
Traded on an average day
€0 EURMedian day 0 shares · 57 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
Sirnaomics Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
HKEX:2257 · Home$3.60 HKD-0.545 (-13.1%)43,700$3.90$4.075$3.60$4.145Close on Nov 20, 2026
Frankfurt:V5Z€0.398 EUR-0.038 (-8.7%)—€0.404€0.404€0.398€0.436Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:V5Z · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.447-0.001-0.2%€0.447€0.447€0.4470
€0.448-0.001-0.2%€0.448€0.448€0.4480
€0.449+0.011+2.5%€0.449€0.449€0.4490
€0.438-0.016-3.5%€0.438€0.438€0.4380
€0.454+0.007+1.6%€0.454€0.454€0.4540
€0.447-0.003-0.7%€0.447€0.447€0.4460
€0.450+0.023+5.4%€0.452€0.454€0.4460
€0.427-0.025-5.5%€0.427€0.431€0.4270
€0.452+0.009+2.0%€0.452€0.452€0.4520
€0.443+0.010+2.3%€0.442€0.446€0.4370
€0.433-0.006-1.4%€0.435€0.436€0.4320
€0.439-0.005-1.1%€0.439€0.439€0.4390
€0.444+0.010+2.3%€0.453€0.455€0.4440
€0.434+0.025+6.1%€0.419€0.439€0.4100
€0.409+0.002+0.5%€0.409€0.409€0.4090
€0.407+0.001+0.2%€0.405€0.412€0.4050
€0.4060.0000.0%€0.404€0.407€0.4040
€0.406+0.007+1.8%€0.406€0.406€0.4060
€0.399-0.008-2.0%€0.401€0.401€0.3970
€0.407+0.002+0.5%€0.407€0.407€0.4070
€0.405-0.001-0.2%€0.405€0.405€0.4050
€0.406-0.019-4.5%€0.414€0.414€0.4050
€0.425+0.019+4.7%€0.405€0.428€0.3980
€0.406+0.001+0.2%€0.406€0.406€0.4060
€0.4050.0000.0%€0.394€0.406€0.3930
€0.405-0.001-0.2%€0.406€0.406€0.4050
€0.406+0.004+1.0%€0.406€0.406€0.4060
€0.402-0.001-0.2%€0.402€0.402€0.4020
€0.403+0.011+2.8%€0.403€0.403€0.4030
€0.392-0.009-2.2%€0.410€0.414€0.3900
€0.401+0.001+0.3%€0.398€0.402€0.3920
€0.400+0.003+0.8%€0.400€0.400€0.4000
€0.397+0.005+1.3%€0.397€0.397€0.3970
€0.392+0.003+0.8%€0.399€0.400€0.3860
€0.389-0.010-2.5%€0.388€0.389€0.3880
€0.399-0.004-1.0%€0.390€0.400€0.3870
€0.403-0.006-1.5%€0.400€0.404€0.4000
€0.409+0.015+3.8%€0.399€0.412€0.3970
€0.394-0.014-3.4%€0.394€0.394€0.3940
€0.408-0.005-1.2%€0.412€0.413€0.4070
€0.413+0.011+2.7%€0.414€0.415€0.4000
€0.402+0.007+1.8%€0.393€0.404€0.3930
€0.395-0.009-2.2%€0.395€0.396€0.3930
€0.4040.0000.0%€0.404€0.404€0.4030
€0.404+0.006+1.5%€0.398€0.405€0.3960
€0.398-0.013-3.2%€0.404€0.405€0.3950
€0.411+0.002+0.5%€0.412€0.415€0.4090
€0.409+0.015+3.8%€0.388€0.415€0.3850
€0.394-0.004-1.0%€0.394€0.394€0.3940
€0.398-0.011-2.7%€0.404€0.404€0.3950
€0.409-0.006-1.4%€0.408€0.411€0.4040
€0.415-0.031-7.0%€0.417€0.422€0.4080
€0.446+0.056+14.4%€0.425€0.452€0.4240
€0.390-0.008-2.0%€0.391€0.392€0.3900
€0.398+0.002+0.5%€0.395€0.401€0.3950
€0.396-0.007-1.7%€0.392€0.399€0.3880
€0.403-0.013-3.1%€0.403€0.403€0.3980
Ticker
Frankfurt:V5Z
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Sirnaomics Ltd. news

Sirnaomics Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 26 in all · newest Nov 4, 2026 · oldest 2023
Decks
11 decks · latest 2024

Where Sirnaomics Ltd. is listed

ListingExchangeCountryCurrency
HKEX:2257 聖諾醫藥 · Home listingHKEXHong KongHKD
Frankfurt:V5Z · This pageFrankfurtGermanyEUR

Valuation

Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$542.4M HKD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Sirnaomics Ltd. · HKEX:2257US$51.13MUS$69.20Mn/an/an/an/an/an/an/a
Xilio Therapeutics, Inc. · NASDAQ:XLOUS$53.40M−US$62.82Mn/a−1.1×n/a0.8×−20.9%0.1×0.76
Impact BioMedical, Inc. · AMEX:IBOUS$53.31MUS$53.29M33.0×1,402×n/a5.3×n/a0.0×0.06
XBiotech Inc. · NASDAQ:XBITUS$52.74M−US$52.29Mn/an/an/a0.4×n/a0.0×0.52
Bonus Biogroup Ltd. · TASE:BONSUS$52.22MUS$54.52Mn/an/an/an/an/an/an/a
iBio, Inc. · NASDAQ:IBIOUS$51.45M−US$23.13Mn/a−21.5×n/a0.7×n/a0.0×2.01
Cinclus Pharma Holding AB · OMXSTO:CINPHAUS$51.17MUS$13.16Mn/a3.8×n/a2.6×−765.8%0.0×n/a
Aldeyra Therapeutics, Inc. · NASDAQ:ALDXUS$50.70MUS$9.72Mn/an/an/a1.4×n/a0.0×0.66
Clene Inc. · NASDAQ:CLNNUS$50.69MUS$58.31Mn/a245×n/an/an/an/a1.48
Acrivon Therapeutics, Inc. · NASDAQ:ACRVUS$49.35M−US$26.60Mn/an/an/a0.7×n/a0.0×2.09
Aptamer Sciences, Inc. · KRX:291650US$49.22MUS$34.46Mn/a8.6×n/a1.6×−215.8%0.0×n/a
Median of the othersUS$51.31MUS$11.44M33.0×6.2×1.1×−215.8%0.0×0.76

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
72.17 HKD · Analysts' mean
EPS, year to Dec 2025
-1.58 · 1 analyst
Revenue, year to Dec 2025
70M · 1 analyst

Team and board

Officers

OfficerRole
H. Fai PoonChairman of the Board, Executive Director and Chief Executive Officer
Poon Hung FaiChairman of the Board and Chief Executive Officer
Jake TianSR VP of R&D
Jerry TseSR VP of Coporate Managment

Board

DirectorRole
H. Fai PoonChairman of the Board, Executive Director and Chief Executive Officer
Poon Hung FaiChairman of the Board and Chief Executive Officer
Lo Yee HangIndependent non-executive Director
Wong Yu Shan EugeneIndependent non-executive Director
Yin HuijunNon-executive Director

Events

QuarterResultsShare move
Q2 2025Aug 28, 2025−5.2%
Quarter to Mar 31, 2025Apr 25, 2025−1.6%
Q4 2024Mar 27, 2025−7.4%
Q4 2021Mar 31, 2022−1.7%

Open Events

Decks

DeckKindSlidesDate
FY2023 Earnings PresentationEarnings35 slides2024
FY2023 Earnings PresentationEarnings35 slides2024
FY2023 Earnings PresentationEarnings35 slides2024
H1 2023 Earnings PresentationEarnings44 slides2023
Investor Presentation (2023)Investor deck20 slides2023
Technical Presentation (March 2022)Technical31 slidesMar 15, 2022
FY2021 Earnings PresentationEarnings25 slidesMarch 2022
FY2021 Earnings PresentationEarnings25 slidesMarch 2022
H1 2022 Earnings PresentationEarnings29 slides2022
Investor Presentation (2022)Investor deck14 slides2022
All 11 decks
DeckKindSlidesDate
Investor Presentation (2022)Investor deck14 slides2022

Open Decks

Financings

RaiseDateIn US dollars
Strategic investment of equity interest (registered capital) in subsidiary Target Company
Closed: CNY 30M raised
Oct 6, 2026US$4.47M
Strategic investment of shares
Announced: about HK$138M · HK$12 a share
Buyers: Bloomage Biotech (approximately HKD 138 million; will hold approximately 9.44% of total issued share capital)
Use of proceeds: Accelerate development and commercialization of aesthetics, longevity intervention and regenerative medicine programs
Sep 7, 2025US$17.7M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue01.78M397.0K705.0K71.0K088.0K
Cost of revenue1.84M579.0K012.7M
Gross profit-1.84M1.20M397.0K705.0K-12.7M88.0K
Research and development8.99M20.8M54.4M67.6M306.0M14.9M10.2M
Selling, general and administrative4.54M17.2M23.2M13.9M16.1M3.81M3.00M
Operating income-15.4M-36.8M-77.1M-91.1M-441.4M-20.1M-15.0M
Depreciation and amortization1.84M5.56M6.16M3.93M1.63M1.04M828.2K
EBITDA-13.5M-31.2M-71.0M-87.2M-439.8M-19.0M-14.2M
Interest expense813.2K1.05M986.0K798.0K2.63M243.0K229.0K
Income before tax-14.6M-50.2M-85.0M-97.4M-1.68B-46.4M-17.1M
Income tax-9.08M-2.86M-2.66M-746.0K
Net income-14.4M-51.4M-78.7M-88.3M-1.66B-43.8M-16.4M
Earnings per share, basic-0.15-0.66-1.03-1.16-111.17-0.50-0.19

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents13.5M11.8M23.9M105.2M212.0M103.1M9.95M
Short-term investments020.0M09.95M
Receivables818.0K639.0K598.0K1.95M80.0K
Current assets15.4M19.5M58.7M117.2M223.8M105.1M21.4M
Property, plant and equipment4.03M7.62M15.5M29.5M14.7M4.45M3.17M
Total assets20.6M28.3M75.8M163.9M240.6M110.2M24.8M
Accounts payable3.16M4.60M3.87M4.89M1.48M782.0K732.0K
Current liabilities38.2M37.2M13.0M14.2M16.2M94.1M2.80M
Long-term debt30.7M29.1M8.44M1.13M0
Total debt9.31M8.06M8.85M10.8M7.04M91.9M1.99M
Total liabilities45.1M44.3M51.3M52.4M30.4M204.4M73.8M
Shareholders' equity-9.91M-1.68M40.2M122.0M211.6M-94.4M-51.8M
Shares outstanding94.5M77.5M76.1M76.0M14.9M88.1M88.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-9.20M-19.7M-70.3M-88.7M-57.0M-19.0M-14.4M
Capital spending-56.0K-108.0K-1.74M-18.8M-5.87M-2.15M-1.19M
Free cash flow-9.25M-19.8M-72.0M-107.5M-62.8M-21.1M-15.6M
Cash from investing23.0K2.14M-5.35M-32.6M-6.04M8.39M1.10M
Cash from financing10.9M5.82M-5.61M15.9M171.0M100.4M11.5M
Share buybacks2.00K-6.48M-10.2M63.9M-614.0K-115.0K
Change in cash1.75M-12.1M-81.3M-106.8M108.9M93.2M-1.74M

Open Financials

Filings

Open Filings

Cap table

Built by 6ix from Sirnaomics Ltd.’s releases · as of Oct 6, 2026

Common shares
111,334,388
Fully diluted
111,334,388

Fully diluted

LineShares
Common shares111,334,388

Share count over time

CountShares
Nov 22, 2026111,334,388

Open Cap table

Shareholders

HolderSharesOf the companyAs of
Quarmaceutical Limited17.5M16.7%Jul 24, 2025
Poon Hung Fai17.7M16.1%Jun 24, 2026
Bloomage Biotechnology (Hong Kong) Limited11.6M11.0%Sep 7, 2025
華熙生物科技股份有限公司11.6M11.0%Sep 7, 2025
華熙昕宇投資有限公司11.6M11.0%Sep 7, 2025
Zhao Yan11.6M11.0%Sep 7, 2025
Lu Yang5.58M5.2%Dec 5, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
H. Fai PoonChairman of the Board, Executive Director and Chief Executive Officer · Since at least Nov 5, 2026
Jake TianSR VP of R&D · Since at least Nov 5, 2026
Jerry TseSR VP of Coporate Managment · Since at least Nov 5, 2026
Lo Yee HangIndependent non-executive Director · Since at least Nov 5, 2026
Poon Hung FaiChairman of the Board and Chief Executive Officer · Since at least Nov 5, 2026
Wong Yu Shan EugeneIndependent non-executive Director · Since at least Nov 5, 2026
Yin HuijunNon-executive Director · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Sirnaomics Ltd.